The global bioconjugation market size is anticipated to reach USD 9.67 billion by 2030 and is projected to grow at a CAGR of 9.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The bioconjugation industry is driven by rising demand for targeted therapeutics and the growing adoption of antibody-drug conjugates (ADCs) in oncology and other treatments. Advancements in precision medicine and site-specific bioconjugation techniques are enhancing drug efficacy driving market expansion. Increasing biopharmaceutical R&D investments are accelerating innovation in biologics, protein conjugation, and nucleic acid-based therapies.
In addition, expanding applications in diagnostics, biomaterials, and drug delivery systems are also fueling growth, particularly with the rising adoption of biosensors and imaging agents. The surge in contract research (CROs) and contract manufacturing (CMOs) services for bioconjugation is further boosting market development. In addition, regulatory support, strategic industry collaborations, and technological advancements in click chemistry and linker technologies are key factors propelling the bioconjugation industry forward.
During the COVID-19 pandemic, the demand for bioconjugation technologies surged, particularly in vaccine development and rapid diagnostics. Bioconjugation played a crucial role in enhancing antigen stability and immune response, improving the efficacy of vaccines such as mRNA-based formulations. In addition, it was widely used in diagnostic assays, enabling faster and more accurate detection of the virus through biosensors and immunoassays. The urgent need for large-scale production led to increased outsourcing to CROs and CMOs, accelerating R&D and manufacturing. These factors underscored the critical role of bioconjugation in pandemic response and vaccine innovation.
Moreover, advancements in precision medicine and biologics are driving the demand for bioconjugation technologies, enabling targeted drug delivery and enhanced therapeutic efficacy. The rise of antibody-drug conjugates (ADCs), protein therapeutics, and gene therapies has increased the need for precise site-specific conjugation and improved linker chemistry. Bioconjugation also plays a key role in personalized treatments, ensuring higher specificity and reduced side effects. As biopharmaceutical R&D expands, the adoption of bioconjugation techniques in drug development, diagnostics, and biomaterials continues to grow, shaping the future of modern medicine.
However, the development of bioconjugated drugs, such as antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs), involves high costs due to expensive raw materials, specialized equipment, and complex manufacturing processes. Producing stable and effective bioconjugates requires advanced linker technologies, site-specific conjugation methods, and stringent quality control, further driving up costs. In addition, high R&D expenses and long drug approval timelines pose significant financial risks for pharmaceutical and biotechnology companies. Regulatory hurdles, extensive clinical trials, and scalability challenges add to the burden, making bioconjugation drug development a capital-intensive and time-consuming process, limiting entry for smaller firms and startups.
The consumables segment led the market with the largest revenue share of 45.45% in 2024, due to the high demand for reagents, linkers, and labeling kits essential for bioconjugation processes. Increasing R&D activities and the growing adoption of antibody-drug conjugates (ADCs) further fueled segment growth. On the other hand, the services segment is expected to grow at the fastest CAGR over the forecast period.
Based on technique, the chemical conjugation segment accounted for the largest market revenue share in 2024, due to its high efficiency, scalability, and widespread use in antibody-drug conjugates (ADCs), protein labeling, and nanoparticle functionalization. Its well-established protocols and compatibility with various biomolecules further drove its dominance. On the other hand, the click chemistry segment is expected to grow at the fastest CAGR over the forecast period.
Based on biomolecule type, the antibodies segment accounted for the largest market revenue share in 2024, due to their crucial role in antibody-drug conjugates (ADCs), targeted therapeutics, and immunoassays. Their high specificity, stability, and widespread application in oncology, infectious diseases, and precision medicine further drive market dominance. On the other hand, the oligonucleotides segment is expected to grow at the fastest CAGR over the forecast period.
Based on application, the therapeutics segment accounted for the largest revenue share in 2024, due to the rising adoption of antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and targeted drug delivery systems. Increasing demand for precision medicine, biologics, and cancer therapies further drives its market leadership. On the other hand, the diagnostics segment is expected to grow at the fastest CAGR over the forecast period.
Based on end use, the pharmaceutical & biotechnological companies segment accounted for the largest market revenue share in 2024, due to increasing R&D investments, demand for targeted therapeutics, and the development of antibody-drug conjugates (ADCs) and biologics. Growing collaborations, outsourcing of bioconjugation services, and advancements in precision medicine further fueled market dominance. On the other hand, the CROs & CMOs segment is expected to grow at the fastest CAGR over the forecast period.
The North America dominated the market with the largest revenue share of 43.75% in 2024, driven by strong biopharmaceutical R&D investments, high adoption of antibody-drug conjugates (ADCs), and advanced healthcare infrastructure. The presence of leading pharmaceutical & biotechnology companies, favorable regulatory support, and growing demand for precision medicine further fueled market growth. On the other hand, the Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period.
Grand View Research has segmented the global bioconjugation market report based on the product & services, biomolecule type, technique, application, end use, and region:
Bioconjugation Product & Services Outlook (Revenue, USD Million, 2018 - 2030)
Consumables
Reagents & Kits
Linker & Crosslinking Reagents & Kits
Labeling Reagents & Kits
Modification Reagents & Kits
Other Reagents & Kits
Labels
Fluorescent Tags
Enzymes
Haptens
Polymers
Bead Coupling
Other Labels
Other Consumables
Instruments
Chromatography Systems
Spectroscopy Instruments
Mass Spectrometers
Flow Cytometers
Electrophoresis Equipment
Filtration Systems
Mixers & Shakers
Incubators
Other Instruments
Service
Custom Synthesis & Conjugation Services
Analytical & Characterization Services
Scale-up & Manufacturing Services
Other Services
Bioconjugation Biomolecule Type Outlook (Revenue, USD Million, 2018 - 2030)
Antibodies
Proteins
Peptides
Oligonucleotides
Other Biomolecules
Bioconjugation Technique Outlook (Revenue, USD Million, 2018 - 2030)
Chemical Conjugation
Enzyme-Mediated Conjugation
Click Chemistry
Photoreactive Crosslinking
Other Techniques
Bioconjugation Application Outlook (Revenue, USD Million, 2018 - 2030)
Therapeutics
Antibody-drug Conjugates
Protein-drug Conjugates
Peptide-drug Conjugates
Other Therapeutic Applications
Research & Development
Diagnostics
Bioconjugation End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology Companies
CROs & CMOs
Academic & Research Institutes
Hospitals, Clinical & Diagnostic Laboratories